FGF-23 is a biomarker of RV dysfunction and congestion in patients with HFrEF.
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68378050%3A_____%2F23%3A00579894" target="_blank" >RIV/68378050:_____/23:00579894 - isvavai.cz</a>
Alternative codes found
RIV/00023001:_____/23:00084199 RIV/00216208:11110/23:10469113 RIV/00216208:11120/23:43926047
Result on the web
<a href="https://www.nature.com/articles/s41598-023-42558-4" target="_blank" >https://www.nature.com/articles/s41598-023-42558-4</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1038/s41598-023-42558-4" target="_blank" >10.1038/s41598-023-42558-4</a>
Alternative languages
Result language
angličtina
Original language name
FGF-23 is a biomarker of RV dysfunction and congestion in patients with HFrEF.
Original language description
There is no biomarker reflecting right ventricular dysfunction in HFrEF patients used in clinical practice. We have aimed to look for a circulating marker of RV dysfunction employing a quantitative proteomic strategy. The Olink Proteomics Multiplex panels (Cardiovascular Disease II, III, Cardiometabolic, and Inflammation Target Panels) identified FGF-23 to be the most differentially abundant (more than 2.5-fold) in blood plasma of HF patients with severe RV dysfunction (n=30) compared to those with preserved RV function (n=31). A subsequent ELISA-based confirmatory analysis of circulating FGF-23 in a large cohort of patients (n=344, 72.7% NYHA III/IV, LVEF 22.5%, 54.1% with moderate/severe RV dysfunction), followed by multivariable regression analysis, revealed that the plasma FGF-23 level was most significantly associated with RV dysfunction grade (p=0.0004) and congestion in the systemic circulation (p=0.03), but not with LV-ejection fraction (p=0.69) or estimated glomerular filtration rate (eGFR, p=0.08). FGF-23 was associated with the degree of RV dysfunction in both sub-cohorts (i.e. in patients with and without congestion, p<0.0001). The association between FGF-23 and RV-dysfunction remained significant after the adjustment for BNP (p=0.01). In contrast, when adjusted for BNP, FGF-23 was no longer associated with LV dysfunction (p=0.59). The Cox proportional hazard model revealed that circulating FGF-23 was significantly associated with adverse outcomes even after adjusting for BNP, LVEF, RV dysfunction grade and eGFR. Circulating FGF-23 isthus a biomarker of right ventricular dysfunction in HFrEF patients regardless of congestion status.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
10608 - Biochemistry and molecular biology
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2023
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Scientific Reports
ISSN
2045-2322
e-ISSN
2045-2322
Volume of the periodical
13
Issue of the periodical within the volume
1
Country of publishing house
US - UNITED STATES
Number of pages
9
Pages from-to
16004
UT code for WoS article
001116558400022
EID of the result in the Scopus database
2-s2.0-85172334413